Clinical Trials on Benign Lymphoproliferative Disorder in China

Total 9216 results

Ruijin Hospital

Recruiting

Cell Free DNA in Mature B-cell Lymphoma

Mature B-Cell Lymphoma

China
Shanghai Cell Therapy Group Co.,Ltd
Institute of Hematology & Blood Diseases Hospital; Tianjin Medical University...

Unknown

Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma

Large B-cell Lymphoma

China
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia

B Cell Leukemia

China
Navy General Hospital, Beijing

Recruiting

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Refractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin Lymphoma

China
Curon Biopharmaceutical (Shanghai) Co.,Ltd

Recruiting

A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Enrolling by invitation

A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas

B Cell Lymphoma

China
Affiliated Hospital to Academy of Military Medical...

Unknown

Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Peking Union Medical College Hospital

Recruiting

Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study

Peripheral T Cell Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

Hodgkin Lymphoma, Adult

China
Sichuan University

Not yet recruiting

Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT

Leukemia, Lymphoid

China
First Affiliated Hospital of Zhejiang University
Cellular Biomedicine Group Ltd.

Active, not recruiting

A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma

Non-Hodgkin's B-cell Lymphoma

China
Sun Yat-sen University

Completed

Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL

Lymphoma, Large B-Cell, Diffuse

China
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute

Completed

Combination of Rituximab and NK Immunotherapy for B Lymphoma

B-cell Lymphoma Recurrent

China
Sun Yat-sen University

Recruiting

GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

Lymphoma, Large B-Cell, Diffuse

China
Nanfang Hospital of Southern Medical University

Recruiting

Thalidomide Maintenance Treatment in DLBCL

Lymphoma, Large B-Cell, Diffuse

China
Shandong Provincial Hospital

Unknown

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

Relapsed/Refractory Non-Hodgkin's Lymphoma

China
Nanfang Hospital of Southern Medical University

Unknown

R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL

Lymphoma, Large B-Cell, Diffuse

China
The First Affiliated Hospital of Soochow University

Recruiting

Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients

Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

Multiple Myeloma

China
Affiliated Hospital of Jiangnan University

Recruiting

89Zr-labeled NY008 PET Imaging in Patients

Multiple Myeloma

China
Beijing Immunochina Medical Science & Technology...

Recruiting

Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma

Multiple Myeloma

China
Shanxi Province Cancer Hospital
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; Jiangsu Province... and other collaborators

Recruiting

Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

Multiple Myeloma

China
The First Affiliated Hospital of Soochow University

Recruiting

Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

Multiple Myeloma

China
The First Affiliated Hospital of Soochow University

Recruiting

Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma

Multiple Myeloma

China
The First Affiliated Hospital of Soochow University

Active, not recruiting

Cohort Construction and Prognostic Model Construction for Multiple Myeloma

Multiple Myeloma

China
Zhongnan Hospital

Completed

Plasma-free Replacement in Patients With Multiple Myeloma

Multiple Myeloma

China
Second Military Medical University
Xiangya Hospital of Central South University; Peking University People's Hospital and other collaborators

Unknown

Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Peking Union Medical College Hospital
Beijing Tongren Hospital; Southern Medical University

Recruiting

Construction of Diagnosis and Treatment System for Primary Vitreoretinal Lymphoma

Primary Vitreoretinal Lymphoma

China
Bioceltech Therapeutics, Ltd.

Recruiting

Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL

T Cell Lymphoblastic Lymphoma

China
Peking Union Medical College Hospital

Recruiting

Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL

Primary Vitreoretinal Lymphoma

China
Peking University

Not yet recruiting

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Peripheral T-cell Lymphoma

China
Hrain Biotechnology Co., Ltd.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Recruiting

Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia

Acute Lymphoblastic Leukemia | CD19-positive

China
Dizal Pharmaceuticals

Suspended

Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)

Non-Hodgkin's B-cell Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Suspended

Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

Neoplasms by Histologic Type | Lymphoma | Hematologic Neoplasms | Advanced Cancer | Immunotherapy | Physiological Effects of Drugs

China
Chinese PLA General Hospital
Shenzhen University General Hospital; Shenzhen University

Unknown

Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin Lymphoma

China
Peking University Cancer Hospital & Institute
Beijing Municipal Administration of Hospitals

Unknown

Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma

Lymphoma, T-Cell, Peripheral

China
Han weidong

Unknown

Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas (CIK)

B Cell Lymphoma | Solid Tumors

China
Peking University People's Hospital

Not yet recruiting

A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.

Relapsed/Refractory Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Multiple Myeloma

China
Yao Liu

Recruiting

Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma

Lymphoma | Multiple Myeloma

China
Shanghai Changzheng Hospital
RenJi Hospital; Huashan Hospital; Shanghai 6th People's Hospital; Huadong Hospital

Recruiting

A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia (CZ-WM01)

Waldenström's Macroglobulinemia

China
Keymed Biosciences Co.Ltd

Recruiting

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Lymphoma | Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

Waldenström Macroglobulinemia

China
Weijun Fu
Nanjing Legend Biotech Co.

Active, not recruiting

A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia (BDH-WM03)

Waldenström Macroglobulinemia

China
Beijing Chao Yang Hospital
Peking University People's Hospital

Unknown

CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma

Extramedullary Plasmacytoma

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

T-lymphoblastic Lymphoma | T-ALL

China
Chinese PLA General Hospital

Recruiting

Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma,B Cell

China
Peking Union Medical College Hospital

Recruiting

Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma

Primary Intraocular Lymphoma

China

Clinical Trials on Benign Lymphoproliferative Disorder in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations